An interventional study of combined cataract and lamellar endothelial keratoplasty in Cataract and Fuchs Endothelial Corneal Dystrophy, sponsored by Universitair Ziekenhuis Brussel. Not yet recruiting at 1 site in Belgium. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Treatment
Among 13 studies in Cataract with a site in Belgium — 3 open to participants now, 3 under way, none of them phase 3. Cataract · Belgium.
Among the 13 studies in Cataract with a site in Belgium, this one is the only one that started in 2026, is one of 7 with no phase, and was the 13th registered.
1,629 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →3 of the 13 studies in Cataract with a site in Belgium are open now. Recruiting first, the newest first:
Visionair Oogzorg · Sites in Belgium
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 141 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 40 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 10 is below the median of 79 across 1,092 interventional studies indexed under Cataract.
Median enrollment 90 across the 9 interventional studies, 37 across the 4 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.
Universitair Ziekenhuis Brussel has 2 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Cataract with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study Overview
This study aims to evaluate the visual outcomes, quality of vision, and patient satisfaction after receiving an extended range PRoF intraocular lens (IOL) during triple Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. This surgery is typically performed to treat patients with both corneal endothelial dysfunction and cataracts. By testing a newer IOL, the PureSee™ extended PRoF IOL, this study hopes to improve the way ophthalmologists plan surgeries and select IOLs for these patients, ultimately helping surgeons optimize the results and expand the options available for people undergoing this procedure.
Purpose of the Study
The goal of this study is to evaluate how well the PureSee™ IOL works in terms of intermediate visual acuity (how well participants can see things at an arm's length). The investigators will also measure the quality of vision, satisfaction, and whether participants need glasses after surgery.
The investigators have set the following goals for this study:
Primary Goal:
To measure how well patients can see intermediate distances (uncorrected intermediate visual acuity, or UIVA) after receiving the PureSee™ IOL during triple DMEK surgery.
Secondary Goals:
To understand how independent patients are from glasses after surgery.
To measure patients' uncorrected and best-corrected visual acuity (sharpness of vision) at distance, intermediate, and near vision after surgery.
To evaluate the uncorrected defocus curve (how the vision of participants changes when focusing at different distances).
To measure contrast sensitivity (how well participants can see in low-light conditions or with subtle contrasts).
Who Can Join This Study?
To participate in this study, participants need to:
Be undergoing triple DMEK surgery for endothelial dysfunction and cataract at the time of enrollment.
Be eligible to receive an extended range of vision IOL as part of the procedure.
This study is looking for patients who are interested in understanding how new IOL technology might improve their postoperative vision quality and reduce their dependence on glasses.
What Will Happen During the Study?
Participants will have their visual outcomes and satisfaction measured at specific times following surgery. This includes:
Testing uncorrected and best-corrected visual acuity at several distances (distance, intermediate, and near).
Completing a survey about how satisfied they are with their vision and how often they need glasses or contact lenses.
Undergoing testing to measure contrast sensitivity (how well participants can see in low-light conditions).
Why Is This Study Important?
The results of this study will help doctors make better decisions about which IOLs to use during triple DMEK surgery. By evaluating the PureSee™ extended PRoF IOL, the investigators hope to expand options for patients and potentially improve visual outcomes and postoperative satisfaction. Ultimately, this study could help improve the quality of life for patients who have both cataracts and endothelial dysfunction.
Study Duration
Participants can expect to undergo their last assessment 6 months post-surgery to track their progress.
Detailed Study Description
This feasibility study is designed to evaluate the visual acuity, quality of vision, refractive outcomes, and patient satisfaction following the implantation of an extended range PRoF intraocular lens (IOL), specifically the PureSee™ IOL, during triple Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. Triple DMEK is a combined procedure for patients with both corneal endothelial dysfunction and cataracts. The main goal of this study is to explore whether the PureSee™ IOL can improve visual outcomes and help reduce the need for glasses, ultimately improving the postoperative experience for these patients.
This study aims to provide valuable data on IOL selection and surgical planning for triple DMEK procedures. The findings will help expand the options available to patients and optimize their visual outcomes after surgery.
Study Objectives
The main objective of this study is to evaluate the visual outcomes, patient satisfaction, and overall success of PureSee™ IOL implantation in a clinical triple DMEK setting. The study will focus on the following specific goals:
Primary Objective
Uncorrected Intermediate Visual Acuity (UIVA):
To evaluate the uncorrected intermediate visual acuity (UIVA) achieved by the PureSee™ IOL in patients undergoing triple DMEK surgery. UIVA will be measured as the primary outcome.
Secondary Objectives
Spectacle Independence:
To assess patient-reported spectacle independence, meaning how often patients can go without glasses or contact lenses following triple DMEK surgery with PureSee™ IOL implantation.
Monocular Visual Acuity:
To measure monocular uncorrected and best-corrected distance, intermediate, and near visual acuity after surgery. This will help determine how well patients can see at various distances (far, near, and intermediate) both without correction (uncorrected) and with glasses or contact lenses (best corrected).
Defocus Curve:
To assess the uncorrected defocus curve, which measures how vision changes as patients focus on objects at different distances, from near to far. This curve helps characterize the range of vision patients experience with the IOL.
Contrast Sensitivity:
To evaluate contrast sensitivity, which tests the ability to see in low-light conditions or perceive subtle contrasts between objects, an important aspect of functional vision for everyday activities such as driving at night or reading.
Study Population
The study will include patients undergoing triple DMEK surgery for the treatment of both endothelial dysfunction and cataracts. Participants will be eligible to receive an extended range PRoF IOL, and must meet the inclusion criteria for the procedure. Specifically, the following criteria will apply:
Patients must be scheduled for triple DMEK surgery.
Patients must be willing to participate in the study and attend follow-up visits.
Study Design
This is a prospective, observational study. All patients will undergo triple DMEK surgery as part of routine clinical care, with the PureSee™ IOL being implanted during the procedure. The study will monitor patients' visual outcomes over several months following surgery.
Interventions
Intervention Group: Patients undergoing triple DMEK surgery will receive the PureSee™ IOL (extended range PRoF IOL).
Outcome Measures
The following primary and secondary outcome measures will be used to evaluate the effectiveness and impact of the PureSee™ IOL:
Primary Outcome
Uncorrected Intermediate Visual Acuity (UIVA): This will be measured at a defined postoperative time point.
Secondary Outcomes
Spectacle Independence: Assessed by patient-reported questionnaires regarding their use of glasses or contact lenses after surgery.
Monocular Visual Acuity:
Uncorrected distance, intermediate, and near visual acuity will be measured for both eyes at multiple postoperative visits.
Best-corrected visual acuity will also be measured for each distance (distance, intermediate, and near).
Defocus Curve:
A series of measurements at different distances will assess the functional range of vision provided by the PureSee™ IOL.
Contrast Sensitivity:
Measured under controlled conditions to evaluate patients' ability to distinguish objects in low-contrast or low-light environments.
Study Duration
Study Enrollment Period: Patients will be recruited over a defined period, with enrollment based on their scheduled triple DMEK surgery.
Follow-up Period: Participants will be followed for six months post-surgery.
Study Significance
The results of this study will provide valuable data on the visual outcomes of patients undergoing triple DMEK surgery with the implantation of the PureSee™ IOL. This new lens may offer significant advantages in terms of visual quality, particularly for intermediate vision, which is often a challenge after traditional IOL implantation in DMEK. This study will help guide IOL selection strategies and improve postoperative care for patients undergoing complex cataract and corneal surgery.
The findings may also contribute to expanding the available options for patients with cataracts and endothelial dysfunction undergoing DMEK, offering the potential for better outcomes and increased spectacle independence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: combined cataract and lamellar endothelial keratoplasty
PureSee™ IOL in combined cataract and lamellar endothelial keratoplasty
Uncorrected intermediate visual acuity on Radner reading chart in LogMAR (logarithm of minimum angle of resolution) scale (range -0.3 till 3),
To evaluate the uncorrected intermediate visual acuity (UIVA) achieved through PureSee™ IOL (extended PRoF IOL) implantation in triple DMEK surgery at 66cm on Radner reading chart in photopic conditions and 100% contrast measured in LogMAR scale (range -0.3 till 3). Lower score indicates better outcome.
Time frame: From enrollment to 6 months post surgery
Patient reported spectacle independence measured with PRSIQ questionaire (patient reported spectacle independence questionaire) and PRVSQ (patient reported visual symptom questionaire) both in Likert scale with component scores from 1 till 6
To assess patient reported spectacle independence in DMEK + extended ProF IOL patients. Lower score indicates better outcome.
Time frame: From enrollment till 6 months post surgery
monocular uncorrected and best corrected distance, intermediate and near visual acuity as well as the uncorrected defocus curve in photopic conditions and 100% contrast measured in LogMAR scale (range -0.3 till 3) at 4m, 66cm and 40cm on EDTRS and Radner
To assess monocular uncorrected and best corrected distance, intermediate and near visual acuity as well as the uncorrected defocus curve in DMEK + extended ProF IOL patients. Lower score indicates better outcome.
Time frame: From enrollment till 6 months post surgery
contrast sensitivity in photopic conditions without glare and mesopic conditions with and without glare with Clinical CSF V.2.0.1, (QVision Academy, Spain) in log10 units, Modulation tranfer function cut-off
To assess contrast sensitivity in DMEK + extended Prof IOL patients. Higher score indicates better result.
Time frame: From enrollment till 6 months post surgery
Plan to share: Undecided
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
Of 300 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 23 months is above that.
Counting every sponsor, half of 490 studies reached it within 17 months; a quarter within 9 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitair Ziekenhuis Brussel →